Clinical Trial Update: Study of Systemic and Ocular Safety and Pharmacokinetics of BI 409306 in Patients With Schizophrenia, Alzheimer's Disease, and Healthy Volunteers [Phase 1]

View source ↗

Summary

Phase 1 study assessing systemic and ocular safety and pharmacokinetics of BI 409306 in schizophrenia, Alzheimer's disease, and healthy volunteers has completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Schizophrenia

Drugs mentioned

• BI 409306

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Schizophrenia, Alzheimer Disease | Phase 1 | Status: COMPLETED | Results posted: 2024-04-19